Protective effects of acetyl-L-carnitine on neurodegenarative changes in chronic cerebral ischemia models and learning-memory impairment in aged rats.

Arch Pharm Res

Preclinical Research Laboratories, Dong-A Pharmaceutical Company, Yongin 446-905, Korea.

Published: January 2012

This study investigated the effects of acetyl-L-carnitine (ALC) in secondarily-induced cerebral chronic ischemia models using rats with permanent ligation of bilateral common carotid arteries (BCCL) and spontaneously hypertensive rats (SHR). Additionally, we used normal aged rats as a primary dementia model. Chronic ALC administration at 100 mg/kg (p.o.) for 4 weeks significantly attenuated neurodegenerative changes. In groups receiving 50 mg/kg or 100 mg/kg, ALC inhibited the active astrocyte increase in cerebral tissues of both BCCL and SHR models. In BCCL rats, ALC administration (50 mg/kg or 100 mg/kg, p.o.) resulted in significant promotion of glutathione levels in brain tissues. We also confirmed behavioral improvement after ALC treatment (100 mg/kg for 8 weeks, p.o.) on learning-memory function using aged rats (18 months old) in a passive avoidance task and preservation of CA1 pyramidal neurons was coincided on histopathological observation. In conclusion, chronic ALC administration may ameliorate cerebral ischemia progress after a cerebrovascular disorder as well as spontaneous ageing-related cerebral dysfunction via hippocampal protection.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12272-012-0116-9DOI Listing

Publication Analysis

Top Keywords

100 mg/kg
16
aged rats
12
alc administration
12
effects acetyl-l-carnitine
8
cerebral ischemia
8
ischemia models
8
chronic alc
8
mg/kg weeks
8
mg/kg 100
8
rats
6

Similar Publications

To illustrate the anti-diabetic properties of Berberis orthobotrys seeds was the aim of the current study. After a series of experiments, two doses of aqueous methanolic extract of the seeds were selected i.e.

View Article and Find Full Text PDF

EVALUATION OF THE EFFECTS OF FAVIPIRAVIR (T-705) ON THE LUNG TISSUE OF HEALTY RATS: AN EXPERIMENTAL STUDY.

Food Chem Toxicol

January 2025

Department of Histology and Embryology, Erciyes University, Faculty of Medicine, 38039 Kayseri, Turkey. Electronic address:

Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor widely used during the COVID-19 pandemic, effectively reduces viral load but has been linked to inflammatory changes in tissues such as the liver and kidneys. High-dose and prolonged use of favipiravir for COVID-19 raises concerns about its potential toxic effects on the lungs, particularly in patients with pre-existing pulmonary conditions. This study investigated favipiravir's effects on lung tissue in healthy rats.

View Article and Find Full Text PDF

This study investigates the effects of lead stress on tomato plants and explores the potential role of plant growth-promoting rhizobacteria (PGPR) to alleviate this stress. The experiment was conducted in pots, introducing varying lead levels (0, 100, 200, 300, 400, and 500 mg kg⁻¹) using lead nitrate. For rhizobacterial inoculation, pre-characterized LTPGP strains S5 Pseudomonas fluorescens A506 and S10 Pseudomonas fluorescens LMG 2189 were used.

View Article and Find Full Text PDF

Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy.

Int J Biol Macromol

January 2025

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.

Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC).

View Article and Find Full Text PDF

Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia.

Bioorg Chem

December 2024

Good Clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. Electronic address:

Inhibition of human concentrative nucleoside transporter 2 (CNT2) could suppress increases in serum urate levels derived from dietary purines. However, the structural basis for substrate recognition of CNT2 is still unknown and only a few inhibitors have been reported. In this study, a homology model of CNT2 was constructed and residues T315, E316, N426, N491, E492, F536 and N538 were identified as binding sites for adenosine through site-directed mutagenesis and a H-adenosine uptake assay.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!